CENTRAL ADMINISTRATIVE CORE
中央行政核心
基本信息
- 批准号:7701170
- 负责人:
- 金额:$ 51.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-06-01 至 2009-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdvertisingAgonistAlcohol or Other Drugs useAnalytical ChemistryAnalytical ToxicologyAreaBedsBiologicalClinicClinicalClinical ResearchClinical TreatmentClinical assessmentsCocaineCocaine AbuseCommunicationComplementCounselingCountyDevelopment PlansDoctor of MedicineDoctor of PhilosophyDopamine D2 ReceptorEducationFacultyFloorFundingHIVHealth Services ResearchHeroin AbuseHospitalsHumanHuman ResourcesIndividualInpatientsInstitutesLaboratoriesLaboratory ResearchLibrariesLocationLong IslandMarijuana DependenceMedicalModelingNatureNew YorkNurse PsychotherapistOperative Surgical ProceduresOpioidOutpatientsPatientsPharmaceutical PreparationsPharmacological TreatmentPilot ProjectsPopulationPresbyterian ChurchPsychiatric NursingPsychiatristPsychologistPsychotherapyResearchResearch PersonnelResearch Project GrantsResearch SupportResourcesRisk AssessmentScreening procedureSelf AdministrationServicesSiteSocioeconomic StatusStructureSubstance abuse problemTestingTimeToxicologyUniversitiesUrinebaselaboratory facilitymedical examinationmembernovel strategiesoutreachpsychosocialresearch facilityresponsetreatment sitetreatment trial
项目摘要
The Central Administrative Core is the coordinating and facilitating structure for the planning, development,
and integration of Projects within the Center. This involves promoting communication among Project researchers
and the individual components within the Center, thus taking full advantage of the interdisciplinary nature of the
Center. The Central Administrative Core will provide administrative support, scientific and medical expertise,
resource and support services (including recruitment, screening, urine toxicology) and support for pilot studies.
The various components of the Central Administrative Core are described below:
1) Administrative and support service component: centralized coordination and support services, including
advertising, recruitment and screening, for the overall Center and major Projects.
2) Research facilities component: library facilities, facilities and support for all urine toxicology and
analytical chemistry, support of at least three inpatient beds and on the General Clinical Research Services located
in the New York State Psychiatric Institute (NYSPI) for Project 1 (Laboratory Model for Heroin Abuse
Medications), support of the Human Laboratory Facility located on the NIH-funded Irving Center for Clinical
Research (ICCR) of Columbia University/Presbyterian Hospital for Project 2 (Mesolimbic DA D l/D2 Receptors
and Response to Cocaine), support of the Opioid Self-administration Laboratory for Project 1, support of
laboratory testing rooms in the Biological Studies Unit (BSU) and outpatient testing rooms within the Substance
Use Research Center (SURC) for Project 5 (Pharmacological Treatment of Marijuana Dependence) and pilot
studies, support of inpatient residential studies using the Residential Laboratory of the SURC for Project 5 and
support of all clinical treatment studies (see below).
3) Clinical component: The clinical component supports an outpatient Substance Treatment Research Service
(STARS) to provide: 1) initial recruitment and screening for all studies in the Center, as well as additional
assessments for all treatment pilot studies and Project 3 (New Approaches to Cocaine Abuse Medications) and
Project 4 (Agonist Treatment of Marijuana Dependence); 2) HIV risk assessment and counseling for all studies in
the Center; and 3) psychotherapy/counseling for Projects 3 and 4, as well as all treatment pilot studies. Projects 3
and 4, as well as and any treatment pilot studies will be carried out at STARS and our new site Project Outreach in
Long Island.
4) Research support component: support of pilot studies and research projects to be conducted by young
faculty members and research fellows. These pilot studies have been an extraordinarily productive aspect of this
MDRC since its inception.
中央行政核心是协调和促进规划、发展、
以及中心内项目的整合。这涉及到促进项目研究人员之间的交流
以及中心内的各个组成部分,从而充分利用
中心。中央行政核心将提供行政支持,科学和医疗专业知识,
资源和支助服务(包括招聘、筛查、尿毒学)以及对试点研究的支助。
以下是中央行政核心的各个组成部分:
1)行政和支助服务构成部分:集中协调和支助服务,包括
广告,招聘和筛选,为整个中心和重大项目。
2)研究设施构成:图书馆设施、设施和所有尿毒学和
分析化学、至少三张住院病床的支助和位于
纽约州精神病研究所(NYSPI)项目1(海洛因滥用的实验室模型)
药物),支持位于美国国立卫生研究院资助的欧文临床中心的人体实验室设施
哥伦比亚大学/长老会医院对项目2(中边缘DA D L/D2受体)的研究
和对可卡因的反应),支持阿片类药物自我管理实验室项目1,支持
生物研究单位(BSU)的实验室测试室和物质内的门诊测试室
将研究中心(SURC)用于项目5(大麻依赖的药物治疗)和试点
研究,为项目5和项目5使用SURC住宿实验室的住院研究提供支持
支持所有临床治疗研究(见下文)。
3)临床部分:临床部分支持门诊物质治疗研究服务
(STAR)提供:1)中心所有研究项目的初步招聘和筛选,以及其他
评估所有治疗试点研究和项目3(治疗可卡因滥用药物的新方法)和
项目4(大麻依赖的激动剂治疗);2)艾滋病毒风险评估和咨询,用于#年的所有研究
中心;以及3)项目3和4的心理治疗/咨询,以及所有治疗试点研究。项目3
和4,以及任何治疗试点研究将在STAR和我们的新场地项目外联中进行
长岛。
4)研究支助部分:支助将由青年进行的试验性研究和研究项目
教职员工和研究员。这些试点研究是这方面非常有成效的一个方面。
MDRC自成立以来就一直是该中心的成员。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Herbert David Kleber其他文献
Herbert David Kleber的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Herbert David Kleber', 18)}}的其他基金
A Study of Anesthesia-Assisted Heroin Detoxification
麻醉辅助海洛因解毒研究
- 批准号:
7045026 - 财政年份:2003
- 资助金额:
$ 51.75万 - 项目类别:
Improving Drug Abuse Treatment by Research and Training
通过研究和培训改善药物滥用治疗
- 批准号:
7643445 - 财政年份:2001
- 资助金额:
$ 51.75万 - 项目类别:
Improving Drug Abuse Treatment by Research and Training
通过研究和培训改善药物滥用治疗
- 批准号:
7864254 - 财政年份:2001
- 资助金额:
$ 51.75万 - 项目类别:
Improving Drug Abuse Treatment by Research and Training
通过研究和培训改善药物滥用治疗
- 批准号:
6612677 - 财政年份:2001
- 资助金额:
$ 51.75万 - 项目类别:
Improving Drug Abuse Treatment by Research and Training
通过研究和培训改善药物滥用治疗
- 批准号:
6361982 - 财政年份:2001
- 资助金额:
$ 51.75万 - 项目类别:
Improving Drug Abuse Treatment by Research and Training
通过研究和培训改善药物滥用治疗
- 批准号:
6915475 - 财政年份:2001
- 资助金额:
$ 51.75万 - 项目类别:
Improving Drug Abuse Treatment by Research and Training
通过研究和培训改善药物滥用治疗
- 批准号:
7147899 - 财政年份:2001
- 资助金额:
$ 51.75万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 51.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 51.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 51.75万 - 项目类别:
Grant-in-Aid for Scientific Research (C)